Levetiracetam Sandoz

Levetiracetam, the active ingredient in Levetiracetam Sandoz, is an anticonvulsant presented as an injectable solution for intravenous use. It is employed as adjunctive therapy to control partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy, and are typically administered under specialist supervision.

GNH USA supplies Levetiracetam Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable quality‑assured batches that meet EU regulatory standards and supporting global procurement teams with responsive logistics and regulatory assistance.

Levetiracetam is an antiepileptic drug used as adjunctive therapy for several seizure types.

- Partial-onset seizures: reduces frequency of focal seizures when added to existing therapy. - Generalized tonic-clonic seizures: helps control convulsive seizures in combination with other antiepileptics. - Myoclonic seizures: diminishes myoclonic jerks as part of a comprehensive seizure management plan.

Levetiracetam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate cranial pain. - Irritability: mood changes including agitation. - Nausea: gastrointestinal discomfort or upset stomach. - Fatigue: reduced energy and endurance.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin blistering and detachment. - Blood dyscrasias: neutropenia, thrombocytopenia, or anemia. - Suicidal thoughts: new or worsening depression or suicidal ideation. - Severe depression: marked mood disturbances requiring medical attention. - Respiratory depression: marked reduction in breathing, especially with concomitant CNS depressants.

When prescribing Levetiracetam, clinicians should consider several safety and handling factors. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic function: monitor liver enzymes in patients with liver disease. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Concomitant CNS depressants: observe for enhanced sedation. - Mood changes: monitor for irritability, depression, or suicidal ideation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin, phenobarbital): may lower levetiracetam plasma levels. - Strong CYP inducers (rifampicin, St. John’s wort): reduce drug exposure. - Other CNS depressants (opioids, benzodiazepines): increase risk of excessive sedation.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Anticoagulants (warfarin): monitor INR as levetiracetam may affect clotting parameters. - Other antiepileptics (valproate, lamotrigine): observe for additive side‑effects. - Immunosuppressants (cyclosporine): watch for altered drug concentrations.